生物仿制药产品开发 1451条(本栏目收费,不能显示细节,电话15274084725)
biologics vs. chemical drugs,416–417 417
case study drug development,420 420
EU market experience,427 427
incentives for biosimilars,428 428
incentivizing market acceptance,431–432 432
innovation benefits,415–416 416
interchangeability,426–427 427
market opportunities,429 429
naming controversy,433 433
patent protection,418–419 419
reimbursement issues,431 431
risk and reward,417–418 418
savings from biosimilars,427–428 428
US biosimilar submissions,430–431 431
competitive ligand binding assay (CLBA),337 337
complementary determining regions (CDR),115,118,179,448 448
complementary determining regions (CDRs),113 113
complement-dependent cytotoxicity (CDC),179 179
confirmation,205–206,340–341 341
cotranslational modifications (CMs),29,112–115 115